SynthesisDigestive diseases and sciences2022
Incidence of Complications from Percutaneous Biopsy in Chronic Liver Disease: A Systematic Review and Meta-Analysis.
Synthesis in Digestive diseases and sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06231082 (Bloody or Well Done. How Would You Like Your Liver Biopsy, Sir? Post Liver bIopsy abdoMinal PaIn as Predictive Factor for Liver bleeDing), which is not on this map. Cited by 64 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bloody or Well Done. How Would You Like Your Liver Biopsy, Sir? Post Liver bIopsy abdoMinal PaIn as Predictive Factor for Liver bleeDing (LIMPID)
Who cites it
64 citing papers in PubMed, 4 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Liver Fat Quantification and Steatosis Grading in Fatty Liver Disease by Magnetic Resonance Imaging: Systematic Review and Meta-Analysis.Journal of gastroenterology and hepatology · 2025Pooled it
- Mechanical rheological model on the assessment of elasticity and viscosity in tissue inflammation: A systematic review.PloS one · 2024Pooled it
- Noninvasive differentiation of porto-sinusoidal vascular disorder from cirrhosis: a systematic review.Abdominal radiology (New York) · 2023Pooled it
- Diagnostic accuracy and clinical impact of MRI-based technologies for patients with non-alcoholic fatty liver disease: systematic review and economic evaluation.Health technology assessment (Winchester, England) · 2023Pooled it
- A cost-effective measure to prevent hemorrhage in ultrasound-guided percutaneous liver biopsy.BMC gastroenterology · 2025Trial
- SomaLogic proteomics reveals new biomarkers and provides mechanistic, clinical insights into Acetyl coA Carboxylase (ACC) inhibition in Non-alcoholic Steatohepatitis (NASH).Scientific reports · 2024Trial
- Coaxial liver biopsy with tract electrocauterization: technique and outcomes in high-risk patients with suspected hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Article
- Can Ultrasound Texture Analysis Differentiate Liver Metastases According to the Histopathological Origin of the Primary Tumor?Journal of clinical medicine · 2026Article
- Noninvasive molecular imaging signatures of histopathological growth patterns in colorectal cancer liver metastases.Clinical & experimental metastasis · 2026Review
- Endo-Hepatology: Paradigm Shift in Endosonographic Diagnosis for Liver Disease to Digestive Endoscopy.Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society · 2026Review
- Liver disease diagnostics and access barriers in African settings: a narrative review.Journal of clinical pathology · 2026Review
- Machine learning-driven clinical decision support for liver cirrhosis: a gut microbiome-based web prediction model with explainable AI integration.BMC gastroenterology · 2026Article
- Cut or Count? Evaluating Advanced Fibrosis Assessment Tools in MASH and Chronic Viral Hepatitis.Biomedicines · 2026Article
- Intraoperative video-based artificial intelligence model exceeding surgeon accuracy for predicting severe fibrosis in minimally invasive liver surgery.Scientific reports · 2026Article
- Portobiliary fistula after liver biopsy in a young transplant patient presenting with GI bleeding and hemorrhagic shock managed by embolization: a case report.International journal of surgery case reports · 2026Article
- Biopsy Needle Integrated with Rotational Oblique Spectral Ultrasound (ROSUS) Imaging.Sensors (Basel, Switzerland) · 2026Article
- Liver Biopsy in Metabolic-Associated Steatotic Liver Disease: Accuracy, Challenges, and Alternatives.Cureus · 2026Review
- Does Gd-EOB-DTPA-enhanced T1 mapping have a role in the staging of fibrosis and inflammation in autoimmune hepatitis? A prospective study.Abdominal radiology (New York) · 2026Article
- Noninvasive strategies for metabolic dysfunction-associated steatotic liver disease assessment and referral in Japan.World journal of gastroenterology · 2026Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundApproaches to liver biopsy have changed over the past decade in patients with chronic liver disease.
aimsWe conducted a systematic review and meta-analysis on the incidence of all complications and technical failure associated with percutaneous liver biopsy.
methodsWe systematically searched PubMed and the Cochrane Library for cohort studies reporting on complications resulting from liver biopsy published between 2010 and 2020. Studies on participants of any age and sex, who underwent any percutaneous biopsy for non-focal liver disease, were selected. All events except mild pain, minor hematoma, vasovagal episodes, fever and fistula were defined as major complications. Random-effect model meta-analyses with and without covariates were performed, to examine the effect of publication year, patient characteristics, outcome collection, and biopsy type on incidences.
resultsWe identified 30 studies reporting on complications resulting from percutaneous liver biopsy procedures (n = 64,356). Incidence of major complications was 2.44% (95% CI 0.85, 6.75), with mortality at 0.01% (95% CI 0.00, 0.11), hospitalization at 0.65% (95% CI 0.38, 1.11), major bleeding at 0.48% (95% CI 0.22, 1.06), and moderate/severe pain at 0.34% (95% CI 0.08, 1.37). Minor complications at 9.53% (95% CI 3.68, 22.5) were mainly pain at 12.9% (95% CI 5.34, 27.9). Technical failure was high at 0.91% (95% CI 0.27, 3.00). Decreasing patient age significantly increased incidence of hospitalization and major bleeding (P < 0.0001). Hospitalization incidence also significantly increased with disease severity.
conclusionsIncidence of major (2.4%) and minor (9.5%) complications, and technical failure (0.91%) in percutaneous liver biopsies continues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.